放射外科与分次放疗治疗海绵窦脑膜瘤:系统综述与Meta分析
该系统综述与Meta分析纳入36项研究、2817例海绵窦脑膜瘤患者,比较伽玛刀放射外科、直线加速器放射外科与分次放疗的局部肿瘤控制与临床结局。单次放射外科治疗的肿瘤体积退缩率高于分次放疗,各技术5年无进展生存率无显著差异,三叉神经及动眼神经相关症状改善率相近。
要点
- 单次放射外科治疗(伽玛刀与直线加速器)诱导的肿瘤体积退缩多于分次放疗(p=0.001)。
- 伽玛刀、直线加速器放射外科与分次放疗的5年无进展生存率分别为93.6%、95.6%、97.4%(p=0.32)。
- 伽玛刀放射外科后21%的患者视力改善,三叉神经症状改善约54%,III-IV-VI脑神经麻痹改善约45%。
核心结论
- 放射外科的肿瘤体积退缩率是分次放疗的两倍。
- 伽玛刀放射外科系列报告21%的病例视力改善。
- 伽玛刀、直线加速器与分次放疗对三叉神经及动眼神经相关脑神经的治疗后临床结局相似。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA指南,检索PubMed、Embase和Medline,筛选425项研究,最终纳入36项符合选择标准的研究(伽玛刀24项、直线加速器5项、分次放疗7项),共2817例患者(伽玛刀放射外科n=2047,直线加速器放射外科n=350,分次放疗n=420)。
主要发现
- 半数患者接受 upfront 放射外科或分次放疗,另半数接受辅助性放射外科或分次放疗(联合治疗或肿瘤复发)。
- 放射外科的平均大体靶体积小于分次放疗(p=0.07)。
- 伽玛刀放射外科的中位边缘剂量为13.9 Gy(范围11至28),直线加速器放射外科为14 Gy(范围12.8至17.7)。
- 分次放疗患者接受平均剂量51.2 Gy(25.5次,每次1.85 Gy)。
- 伽玛刀放射外科、直线加速器放射外科与分次放疗的平均总体随访时间分别为48个月(范围15至89)、69个月(范围46至87)和59.5个月(范围33至83)。
关键数值与推荐
- 伽玛刀放射外科、直线加速器放射外科与分次放疗的5年无进展生存率分别为93.6%、95.6%和97.4%(p=0.32,Kruskal-Wallis检验)。
- 单次放射外科治疗(伽玛刀与直线加速器放射外科)诱导的肿瘤体积退缩多于分次放疗(p=0.001)。
- 肿瘤复发或进展范围为3%至5.8%,各模式间无统计学显著差异(p>0.05)。
- 三叉神经症状改善约54%,III-IV-VI脑神经麻痹改善约45%。
- 伽玛刀放射外科后视力改善21%(其他模式数据不足);新发神经功能缺损为5%至7.5%;不良放射效应(所有技术合并)为4.6%至9.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Radiosurgery (RS) and fractionated radiotherapy (FRT) are part of the therapeutic armamentarium for the management of cavernous sinus meningiomas. We propose a systematic review of the local tumor control and clinical outcomes after monofractionated radiosurgical treatment, including gamma knife radiosurgery (GKRS) and linear accelerator (Linac RS), or fractionated radiotherapy. MATERIALS AND METHODS: The current review and meta-analysis adhered to the PRISMA guidelines. We performed a search in PubMed, Embase, and Medline based on the following mesh terms, used alone or in diverse combinations, in both title and abstract: "cavernous sinus," "meningioma," "radiosurgery," "gamma knife," "linac," "cyberknife," and "radiotherapy". We screened 425 studies. We selected 36 studies, matching all selection criteria: 24 for GK, 5 for Linac, and 7 for FRT. RESULTS: Were included 2817 patients (GKRS, n = 2047, LinacRS, n = 350, FRT, n = 420). Half of patients benefited from upfront RS or FRT; the other half benefited from adjuvant RS or FRT (combined approach or tumor recurrence). The mean gross target volume (GTV) was smaller for RS as compared to FRT (p = 0.07). The median marginal doses were 13.9 Gy (range, 11 to 28) for GKRS and 14 Gy (range, 12.8 to 17.7) for LinacRS. For FRT, patients received a mean dose of 51.2 Gy (25.5 fractions, 1.85 Gy each). The mean overall follow-up values were 48 months (range, 15 to 89) for GKRS, 69 months (range, 46 to 87) for Linac, and 59.5 months (range, 33 to 83) for FRT. PFS at 5 years for GKRS, LinacRS, and FRT were respectively 93.6%, 95.6%, and 97.4% (p = 0.32, the Kruskal-Wallis). Monofractionated treatments (GKRS and LinacRS) induced more tumor volume regression than FRT (p = 0.001). Tumor recurrence or progression ranged between 3 and 5.8%, without statistically significant differences between modalities (p > 0.05). Trigeminal symptoms improved in approximately 54%, and III-IV-VI cranial nerves (CN) palsies improved in approximately 45%. After GKRS, visual acuity improved in 21% (not enough data available for other modalities). De novo deficits occurred in 5 to 7.5%. Adverse radiation effects appeared in 4.6 to 9.3% (all techniques pooled). CONCLUSION: RS achieved a twice-higher rate of tumor volume regression than FRT. GKRS series reported an improvement in visual acuity in 21% of the cases. GKRS, Linac, and FRT provided similar clinical post therapeutic outcomes for the trigeminal and oculomotor CN.
引用
- Leroy HA, Tuleasca C, Reyns N, et al. Radiosurgery and fractionated radiotherapy for cavernous sinus meningioma: a systematic review and meta-analysis. Acta Neurochir (Wien). 2018. PMID: 30393820. doi:10.1007/s00701-018-3711-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。